IFNA1 and neoplasm: Downregulation of both type I and II IFN-mediated pathways have been described as mechanisms involved in resistance to CPI- and adoptive cell therapy in melanoma and lung cancer, indicating the potential of interference in these pathways to increase anti-tumor immunity [4,5,6,10,93,94,95,96].